ZS Pharma Eyes $214M Offering To Commercialize Lead Drug
ZS Pharma Inc., a biopharmaceutical company developing treatments for renal, cardiovascular and liver metabolic disorders, announced an upsized public offering on Tuesday that could fetch up to $213.6 million, joining the...To view the full article, register now.
Already a subscriber? Click here to view full article